Obesity and Atrial Fibrillation: A Comprehensive Review
By: Jonathan Na, Sai Sita Garapati and Adi Lador
References
- NLM [Internet]. Bethesda, MD: National Library of Medicine; c2024.
Committee on Standards for Systematic Reviews of Comparative Effectiveness R . Eden J, Levit L, Berg A, Morton S, eds. Finding What Works in Health Care: Standards for Systematic Reviews; 2011 [cited 2024 Dec 9]. Available from:https://pubmed.ncbi.nlm.nih.gov/24983062/ - Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014 Feb 25;129(8):837-47. doi: 10.1161/CIRCULATIONAHA.113.005119
- Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024 Jan 2;149(1):e1-e156. doi: 10.1161/CIR.0000000000001193
- Dieleman JL, Cao J, Chapin A, et al. US Health Care Spending by Payer and Health Condition, 1996-2016. JAMA. 2020 Mar 3;323(9):863-884. doi: 10.1001/jama.2020.0734
- Pouwels S, Topal B, Knook MT, et al. Interaction of obesity and atrial fibrillation: an overview of pathophysiology and clinical management. Expert Rev Cardiovasc Ther. 2019 Mar;17(3):209-223. doi: 10.1080/14779072.2019.1581064
- Wang TJ, Parise H, Levy D, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA. 2004 Nov 24;292(20):2471-7. doi: 10.1001/jama.292.20.2471
- Dircks D, Khaing E, Aroudaky A, et al. Representation of obesity in contemporary atrial fibrillation ablation randomized controlled trials. J Cardiovasc Electrophysiol. 2024 Oct;35(10):2006-2016. doi: 10.1111/jce.16396
- Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002 Oct 9;288(14):1723-7. doi: 10.1001/jama.288.14.1723
- Temple NJ. The Origins of the Obesity Epidemic in the USA-Lessons for Today. Nutrients. 2022 Oct 12;14(20):4253. doi: 10.3390/nu14204253.
- Schnabel RB, Yin X, Gona P, Larson MG, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet. 2015 Jul 11;386(9989):154-62. doi: 10.1016/S0140-6736(14)61774-8
- Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. Int J Stroke. 2021 Feb;16(2):217-221. doi: 10.1177/1747493019897870
- Ward ZJ, Bleich SN, Cradock AL, et al. Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity. N Engl J Med. 2019 Dec 19;381(25):2440-2450. doi: 10.1056/NEJMsa1909301
- Karam BS, Chavez-Moreno A, Koh W, Akar JG, Akar FG. Oxidative stress and inflammation as central mediators of atrial fibrillation in obesity and diabetes. Cardiovasc Diabetol. 2017 Sep 29;16(1):120. doi: 10.1186/s12933-017-0604-9
- Guo Y, Lip GY, Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol. 2012 Dec 4;60(22):2263-70. doi: 10.1016/j.jacc.2012.04.063
- Busebee B, Ghusn W, Cifuentes L, Acosta A. Obesity: A Review of Pathophysiology and Classification. Mayo Clin Proc. 2023 Dec;98(12):1842-1857. doi: 10.1016/j.mayocp.2023.05.026
- Liew R, Khairunnisa K, Gu Y, et al. Role of tumor necrosis factor-α in the pathogenesis of atrial fibrosis and development of an arrhythmogenic substrate. Circ J. 2013;77(5):1171-9. doi: 10.1253/circj.cj-12-1155
- Kao YH, Chen YC, Cheng CC, Lee TI, Chen YJ, Chen SA. Tumor necrosis factor-alpha decreases sarcoplasmic reticulum Ca2+-ATPase expressions via the promoter methylation in cardiomyocytes. Crit Care Med. 2010 Jan;38(1):217-22. doi: 10.1097/CCM.0b013e3181b4a854
- Sha R, Baines O, Hayes A, et al. Impact of Obesity on Atrial Fibrillation Pathogenesis and Treatment Options. J Am Heart Assoc. 2024 Jan 2;13(1):
e032277 . doi: 10.1161/JAHA.123.032277 - Chen S. Catheter ablation of atrial fibrillation in “very severe” obese patients (BMI ≥ 40): Insights from “the ICE-Obese Extreme” study. J Cardiovasc Electrophysiol. 2024 Aug;35(8):1711-1713. doi: 10.1111/jce.16361
- Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004 Dec;114(12):1752-61. doi: 10.1172/JCI21625
- Yang R, Ernst P, Song J, et al. Mitochondrial-Mediated Oxidative Ca(2+)/Calmodulin-Dependent Kinase II Activation Induces Early Afterdepolarizations in Guinea Pig Cardiomyocytes: An In Silico Study. J Am Heart Assoc. 2018 Aug 7;7(15):
e008939 . doi: 10.1161/JAHA.118.008939 - Ihara K, Sasano T. Role of Inflammation in the Pathogenesis of Atrial Fibrillation. Front Physiol. 2022 Apr 14;13:862164. doi: 10.3389/fphys.2022.862164
- Njoku A, Kannabhiran M, Arora R, et al. Left atrial volume predicts atrial fibrillation recurrence after radiofrequency ablation: a meta-analysis. Europace. 2018 Jan 1;20(1):33-42. doi: 10.1093/europace/eux013
- Kurotobi T, Iwakura K, Inoue K, et al. The significance of the shape of the left atrial roof as a novel index for determining the electrophysiological and structural characteristics in patients with atrial fibrillation. Europace. 2011 Jun;13(6):803-8. doi: 10.1093/europace/eur039
- Cunha PS, Laranjo S, Heijman J, Oliveira MM. The Atrium in Atrial Fibrillation - A Clinical Review on How to Manage Atrial Fibrotic Substrates. Front Cardiovasc Med. 2022 Jul 4;9:879984. doi: 10.3389/fcvm.2022.879984
- Roselli C, Rienstra M, Ellinor PT. Genetics of Atrial Fibrillation in 2020: GWAS, Genome Sequencing, Polygenic Risk, and Beyond. Circ Res. 2020 Jun 19;127(1):21-33. doi: 10.1161/CIRCRESAHA.120.316575
- Šket R, Slapnik B, Kotnik P, et al. Integrating Genetic Insights, Technological Advancements, Screening, and Personalized Pharmacological Interventions in Childhood Obesity. Adv Ther. 2024 Nov 13. doi: 10.1007/s12325-024-03057-8
- Wang N, Yu Y, Sun Y, et al. Acquired risk factors and incident atrial fibrillation according to age and genetic predisposition. Eur Heart J. 2023 Dec 14;44(47):4982-4993. doi: 10.1093/eurheartj/ehad615
- Schwartz AR, Patil SP, Laffan AM, Polotsky V, Schneider H, Smith PL. Obesity and obstructive sleep apnea: pathogenic mechanisms and therapeutic approaches. Proc Am Thorac Soc. 2008 Feb 15;5(2):185-92. doi: 10.1513/pats.200708-137MG
- Peppard PE, Young T, Palta M, Dempsey J, Skatrud J. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA. 2000 Dec 20;284(23):3015-21. doi: 10.1001/jama.284.23.3015
- Tamayo-Trujillo R, Paz-Cruz E, Cadena-Ullauri S, et al. Exploring Atrial Fibrillation: Understanding the Complex Relation Between Lifestyle and Genetic Factors. J Med Cases. 2024 Aug;15(8):186-194. doi: 10.14740/jmc4250
- Fitch AK, Bays HE. Obesity definition, diagnosis, bias, standard operating procedures (SOPs), and telehealth: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obes Pillars. 2022 Jan 15;1:100004. doi: 10.1016/j.obpill.2021.100004
- Seyed Ahmadi S, Svensson AM, Pivodic A, Rosengren A, Lind M. Risk of atrial fibrillation in persons with type 2 diabetes and the excess risk in relation to glycaemic control and renal function: a Swedish cohort study. Cardiovasc Diabetol. 2020 Jan 18;19(1):9. doi: 10.1186/s12933-019-0983-1
- Stoicescu L, Crişan D, Morgovan C, Avram L, Ghibu S. Heart Failure with Preserved Ejection Fraction: The Pathophysiological Mechanisms behind the Clinical Phenotypes and the Therapeutic Approach. Int J Mol Sci. 2024 Jan 8;25(2):794. doi: 10.3390/ijms25020794
- Lee DS, Gona P, Vasan RS, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute. Circulation. 2009 Jun 23;119(24):3070-7. doi: 10.1161/CIRCULATIONAHA.108.815944
- Middeldorp ME, Kamsani SH, Sanders P. Obesity and atrial fibrillation: Prevalence, pathogenesis, and prognosis. Prog Cardiovasc Dis. 2023 May-Jun;78:34-42. doi: 10.1016/j.pcad.2023.04.010
- Goette A, Corradi D, Dobrev D, et al. Atrial cardiomyopathy revisited-evolution of a concept: a clinical consensus statement of the European Heart Rhythm Association (EHRA) of the ESC, the Heart Rhythm Society (HRS), the Asian Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS). Europace. 2024 Aug 30;26(9):
euae204 . doi: 10.1093/europace/euae204 - Shihab HM, Meoni LA, Chu AY, et al. Body mass index and risk of incident hypertension over the life course: the Johns Hopkins Precursors Study. Circulation. 2012 Dec 18;126(25):2983-9. doi: 10.1161/CIRCULATIONAHA.112.117333
- Boriani G, Proietti M. Atrial fibrillation prevention: an appraisal of current evidence. Heart. 2018 Jun;104(11):882-887. doi: 10.1136/heartjnl-2017-311546
- Karakasis P, Ktenopoulos N, Pamporis K, et al. Efficacy and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients (BMI ≥ 30 kg/m2) with Atrial Fibrillation or Venous Thromboembolism: An Updated Systematic Review and Meta-Analysis. J Clin Med. 2024 Jun 27;13(13):3784. doi: 10.3390/jcm13133784
- Badheka AO, Rathod A, Kizilbash MA, et al. Influence of obesity on outcomes in atrial fibrillation: yet another obesity paradox. Am J Med. 2010 Jul;123(7):646-51. doi: 10.1016/j.amjmed.2009.11.026
- Proietti M, Boriani G. Obesity Paradox in Atrial Fibrillation: Implications for Outcomes and Relationship with Oral Anticoagulant Drugs. Am J Cardiovasc Drugs. 2020 Apr;20(2):125-137. doi: 10.1007/s40256-019-00374-0
- Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA. 2013 Nov 20;310(19):2050-60. doi: 10.1001/jama.2013.280521
- Donnellan E, Wazni OM, Kanj M, et al. Impact of risk-factor modification on arrhythmia recurrence among morbidly obese patients undergoing atrial fibrillation ablation. J Cardiovasc Electrophysiol. 2020 Aug;31(8):1979-1986. doi: 10.1111/jce.14607
- Pathak RK, Middeldorp ME, Meredith M, et al. Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort: A Long-Term Follow-Up Study (LEGACY). J Am Coll Cardiol. 2015 May 26;65(20):2159-69. doi: 10.1016/j.jacc.2015.03.002
- Bohne LJ, Jansen HJ, Dorey TW, et al. Glucagon-Like Peptide-1 Protects Against Atrial Fibrillation and Atrial Remodeling in Type 2 Diabetic Mice. JACC Basic Transl Sci. 2023 Mar 15;8(8):922-936. doi: 10.1016/j.jacbts.2023.01.005
- Machado Carvalhais R, Siochi C, Harutyunyan G, et al. Differences in the Impact of Obesity and Bariatric Surgery on Patients Hospitalized for Atrial Flutter and Atrial Fibrillation: A Nationwide Analysis, 2016-2020. Cureus. 2024 Jun 13;16(6):
e62284 . doi: 10.7759/cureus.62284 - Smit C, De Hoogd S, Brüggemann RJM, Knibbe CAJ. Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters. Expert Opin Drug Metab Toxicol. 2018 Mar;14(3):275-285. doi: 10.1080/17425255.2018.1440287
- Malik AH, Yandrapalli S, Shetty S, et al. Impact of weight on the efficacy and safety of direct-acting oral anticoagulants in patients with non-valvular atrial fibrillation: a meta-analysis. Europace. 2020 Mar 1;22(3):361-367. doi: 10.1093/europace/euz361
- Patel SM, Braunwald E, Steffel J, et al. Efficacy and Safety of Non-Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of 4 Randomized Clinical Trials of Patients With Atrial Fibrillation. Circulation. 2024 Mar 19;149(12):932-943. doi: 10.1161/CIRCULATIONAHA.123.066279
- Leong R, Chu DK, Crowther MA, Mithoowani S. Direct oral anticoagulants after bariatric surgery-What is the evidence? J Thromb Haemost. 2022 Sep;20(9):1988-2000. doi: 10.1111/jth.15823
- Galletti F, Fasano ML, Ferrara LA, Groppi A, Montagna M, Mancini M. Obesity and beta-blockers: influence of body fat on their kinetics and cardiovascular effects. J Clin Pharmacol. 1989 Mar;29(3):212-6. doi: 10.1002/j.1552-4604.1989.tb03315.x
- Abernethy DR, Schwartz JB. Verapamil pharmacodynamics and disposition in obese hypertensive patients. J Cardiovasc Pharmacol. 1988 Feb;11(2):209-15. PMID: 2452316.
- Shaikh F, Wynne R, Castelino RL, Davidson PM, Inglis SC, Ferguson C. Effect of Obesity on the Use of Antiarrhythmics in Adults With Atrial Fibrillation: A Narrative Review. Clin Cardiol. 2024 Aug;47(8):
e24336 . doi: 10.1002/clc.24336 - Ornelas-Loredo A, Kany S, Abraham V, et al. Association Between Obesity-Mediated Atrial Fibrillation and Therapy With Sodium Channel Blocker Antiarrhythmic Drugs. JAMA Cardiol. 2020 Jan 1;5(1):57-64. doi: 10.1001/jamacardio.2019.4513
- Darbar D, Kannankeril PJ, Donahue BS, et al. Cardiac sodium channel (SCN5A) variants associated with atrial fibrillation. Circulation. 2008 Apr 15;117(15):1927-35. doi: 10.1161/CIRCULATIONAHA.107.757955
- Lafuente-Lafuente C, Alvarez JC, Leenhardt A, et al. Amiodarone concentrations in plasma and fat tissue during chronic treatment and related toxicity. Br J Clin Pharmacol. 2009 May;67(5):511-9. doi: 10.1111/j.1365-2125.2009.03381.x
- Zhuang J, Lu Y, Tang K, Peng W, Xu Y. Influence of body mass index on recurrence and quality of life in atrial fibrillation patients after catheter ablation: a meta-analysis and systematic review. Clin Cardiol. 2013 May;36(5):269-75. doi: 10.1002/clc.22108
- Zghaib T, Ipek EG, Zahid S, et al. Association of left atrial epicardial adipose tissue with electrogram bipolar voltage and fractionation: Electrophysiologic substrates for atrial fibrillation. Heart Rhythm. 2016 Dec;13(12):2333-2339. doi: 10.1016/j.hrthm.2016.08.030
DOI: https://doi.org/10.14797/mdcvj.1516 | Journal eISSN: 1947-6108
Language: English
Page range: 35 - 43
Submitted on: Nov 1, 2024
Accepted on: Nov 22, 2024
Published on: Feb 18, 2025
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
Keywords:
© 2025 Jonathan Na, Sai Sita Garapati, Adi Lador, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.